×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| SOLARA ACTIVE PHARMA SCIENCES | 3201.3 | 105.2 | 3191.5 | 2.46 | 3,010 | 123.0 |
| MOREPEN LABORATORIES LTD. | 3953.77 | 80.61 | 3912.84 | 0.15 | 2797 | 30.2 |
| PANACEA BIOTEC LTD. | 1172.0 | -67.0 | 1122.5 | -1.09 | 2762 |
SOLARA ACTIVE PHARMA SCIENCES LIMITED, with Security Code 541540, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 394.8 | 380.6 | 352.3 | 425.2 | 248.7 | 299.4 | 363.5 | 347.0 | 300.3 | 273.0 |
| Expenses | 349.5 | 329.1 | 333.2 | 387.6 | 410.4 | 289.6 | 321.3 | 285.6 | 242.6 | 230.4 |
| Operating Profit | 45.3 | 51.6 | 19.1 | 37.7 | -161.7 | 9.8 | 42.2 | 61.3 | 57.7 | 42.6 |
| OPM % | 11.47% | 13.54% | 5.43% | 8.86% | -65% | 3.27% | 11.62% | 17.67% | 19.21% | 15.61% |
| Other Income | 6.8 | 5.1 | 2.1 | -2.3 | -62.3 | -121.7 | 1.4 | 0.3 | 1.5 | 6.0 |
| Interest | 23.6 | 22.0 | 25.5 | 24.5 | 25.4 | 30.6 | 30.9 | 28.3 | 26.5 | 29.1 |
| Depreciation | 27.9 | 26.4 | 25.8 | 26.1 | 26.0 | 25.1 | 25.1 | 25.3 | 24.5 | 24.3 |
| Profit before tax | 0.5 | 8.3 | -30.1 | -11.7 | -212.6 | -44.3 | -12.3 | 8.0 | 8.1 | -4.8 |
| Tax % | -20.8% | -22.3% | -34% | 0% | 0% | 53% | 0% | 0% | 0% | 0% |
| Net Profit | 0.4 | 6.5 | -19.9 | -15.3 | -275.3 | -256.4 | -12.3 | 8.0 | 8.1 | -4.9 |
| EPS in Rs | 0.12 | 1.79 | -5.52 | -4.24 | -76.49 | -71.23 | -3.2 | 2.11 | 2.47 | 0 |
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 380.6 | 352.3 | 425.2 | 248.7 | 299.4 | 363.5 | 347.0 | 300.3 | 273.0 | 319.2 |
| Expenses | 331.9 | 333.2 | 387.6 | 410.4 | 289.7 | 321.6 | 285.6 | 242.6 | 227.6 | 262.1 |
| Operating Profit | 48.8 | 19.1 | 37.6 | -161.7 | 9.8 | 41.9 | 61.3 | 57.7 | 45.4 | 57.0 |
| OPM % | 12.81% | 5.43% | 8.85% | -65.01% | 3.26% | 11.53% | 17.67% | 19.21% | 16.64% | 17.87% |
| Other Income | 4.7 | 2.0 | -4.0 | -62.3 | -120.5 | 0.6 | 0.3 | 1.5 | 6.0 | 1.0 |
| Interest | 22.0 | 24.6 | 24.4 | 25.4 | 30.7 | 30.9 | 28.3 | 26.5 | 29.1 | 23.9 |
| Depreciation | 26.5 | 25.9 | 26.2 | 26.0 | 25.3 | 25.1 | 25.3 | 24.5 | 24.3 | 23.6 |
| Profit before tax | 5.0 | -29.4 | -11.8 | -212.6 | -44.5 | -13.5 | 8.0 | 8.1 | -2.0 | 10.5 |
| Tax % | -25.4% | -34.9% | 0% | 0% | 53.3% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 3.8 | -19.1 | -17.1 | -275.3 | -255.5 | -13.5 | 8.0 | 8.1 | -2.1 | 10.5 |
| EPS in Rs | 1.05 | -5.43 | -4.77 | -76.49 | -70.93 | -3.5 | 2.54 | 2.03 | 0 | 2.46 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -1% |
| 3 Years: | 0% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 26% |
| TTM: | 100% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 2% |
| 3 Years: | 8% |
| 1 Year: | -2% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -1% |
| 3 Years: | 0% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -66% |
| 3 Years: | 26% |
| TTM: | 100% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 2% |
| 3 Years: | 8% |
| 1 Year: | -2% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|